| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4023632 | Journal Français d'Ophtalmologie | 2015 | 8 Pages |
Abstract
The intravitreal dexamethasone implant appears to be an effective second-line treatment even in patients with diabetic ME after failure or in the case of contraindication of anti-VEGF. It is also effective and well tolerated in patients with ME after RD, as well as in patients with Irvine-Gass syndrome.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
A. Degoumois, J. Akesbi, C. Laurens, F.-T. Rodallec, R. Adam, E. Blumen-Ohana, O. Laplace, C. Virevialle, B. Le Dû, V. Guyader, J.-P. Nordmann,